PuSH - Publikationsserver des Helmholtz Zentrums München

Bette, S.* ; Barz, M.* ; Wiestler, B.* ; Huber, T.* ; Gerhardt, J.* ; Buchmann, N.* ; Combs, S.E. ; Schmidt-Graf, F.* ; Delbridge, C.* ; Zimmer, C.* ; Kirschke, J.S.* ; Meyer, B.* ; Ryang, Y.M.* ; Ringel, F.* ; Gempt, J.*

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

Ann. Surg. Oncol. 25, 1-7 (2017)
Forschungsdaten DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy. The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy. Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm(3)). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen. Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001). In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.041
1.596
15
22
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Newly-diagnosed Glioblastoma; Adjuvant Temozolomide; Molecular Markers; Ncic Trial; Phase-iii; Survival; Extent; Surgery; Multiforme; Eortc
Sprache englisch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 1068-9265
e-ISSN 1534-4681
Quellenangaben Band: 25, Heft: 2, Seiten: 1-7 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
PubMed ID 29159745
Scopus ID 85034615968
Erfassungsdatum 2017-12-11